This webconference is supported by an independent educational grant provided by Insulet Corporation.

Consortium for Integrated Diabetes Device Education

TM Multi-Award WinningMedical Education>20,100 Members and growing

Forward this Program GuidecgmEDUCATION.net/guide

Jointly provided by

7pm ET | 6pm CT | 5pm MT | 4pm PT

Thursday January 14, 2021

Approved for 1.5 AMA PRA Category 1 Credit(s)™1.5 ACPE Contact Hours (0.15 CEUs)

(free) CME/CPEDiabetes Technology Roundtable IVNovel Insulin Pumps and AID Systems: Platforms · Form Factors · Functionality

Gregory P. ForlenzaChildren’s HospitalAssistant Professor

Barbara Davis Diabetes Center Anschutz Campus School of Medicine

University of ColoradoAurora, Colorado

MDGrazia Aleppo

Professor of MedicineDirector

Diabetes Education ProgramAssociate Chief for Clinical Affairs

Division of EndocrinologyMetabolism and Molecular Medicine

Feinberg School of Medicine Northwestern University

Chicago, Illinois

MD, FACE, FACPJennifer Sherr

Associate Professor in Pediatrics Yale School of Medicine New Haven, Connecticut

MD, PhDIrl B. HirschProfessor of MedicineDiabetes Treatment and Teaching Chair

University of WashingtonMedicine Diabetes Institute

Seattle, Washington

MD

CHAIRPERSON

Consortium for Integrated Diabetes Device Education

TM

cgmeducation.net/query

INTENDED AUDIENCEDiabetologists, Endocrinologists, Primary Care Physicians, Nurse Practitioners, Pharmacists, CertifiedDiabetes Educators and other Health Care Professionals interested in the management of diabetes.

EDUCATIONAL OBJECTIVESAt the conclusion of this program, participants will be better able to:1. Understand medical management and managed care of diabetes, including via telemedicine,

best practices when utilizing insulin pumps for T1.2. Define how AID (and HCL) systems with insulin pumps enable patients with T1 diabetes to improve

TIR and other outcomes. 3. List specific features of AID (and HCL) systems with insulin pumps that are convenient and clinically

important to providers and patients with T1.4. Apply the newest technology developments in AID (and HCL) systems, and recognize their

clinical importance.

CPE EDUCATIONAL OBJECTIVESAt the completion of this activity, the participant will be able to:1. Identify best practices when utilizing insulin pumps for the medical management and managed care of

T1 diabetes, including via telemedicine2. Define how AID (and HCL) systems with insulin pumps enable patients with T1 diabetes to improve TIR

and other outcomes.3. List specific features of AID (and HCL) systems with insulin pumps that are convenient and clinically

important to providers and patients with T1.4. Recognize the newest technology developments in AID (and HCL) systems and their clinical importance.

ACCREDITATION AND DESIGNATION This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC and CogniMed Inc. Evolve Medical Education LLC is accredited by the ACCME to provide continuing medical education for physicians.

Evolve Medical Education LLC designates this live activity for a maximum of 1.5 AMA PRA Category1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of theirparticipation in the activity.

Accreditation StatementThe University of South Carolina College of Pharmacy is accredited by the AccreditationCouncil for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based activity is accredited for 1.5 home study contact hours (0.15 CEU) forpharmacists, ACPE UAN 0062-9999-21-013-H01-P (release date: January 14, 2021; expiration date:January 14, 2022). To claim credit, participants must sign-in/register and participate in the entireactivity, engaging in all active learning activities and completing all required learning assessments.No partial credit will be issued. Participants must complete an online evaluation at http://cop.sc.learningexpressce.com within 30 days (providing their correct NABP e-Profile ID and month/dayof birth) in order to ensure credit is reported to the NABP CPE Monitor. Detailed instructions willbe provided after participating in the activity. The CPE Monitor will automatically reject all creditclaimed and reported greater than 60 days from the date of participation. Visit our website to contactus with any questions.

DISCLOSURE POLICYIt is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests: Chair: Irl B. Hirsch, MD and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support from Medtronic and Insulet; Consultant for Abbott and Bigfoot.

Faculty: Grazia Aleppo, MD, FACE, FACP and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support from Dexcom, Insulet and Eli Lilly; Consultant for Insulet; Speakers List for Dexcom.

Gregory P. Forlenza, MD and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant for as well as Grant/Research Support from Abbott, Beta Bionics, Dexcom, Lilly, Insulet, Medtronic and Tandem.

Jennifer Sherr, MD, PhD and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support from Dexcom, Insulet and Medtronics Diabetes; Consultant for Cecelia Health, Eli Lilly, Insulet, Lexicon, Medtronic, Sanofi, T1D Fund; Speaker List for Eli Lilly, Medtronic.

EDITORIALThe Evolve staff and planners have no financial relationships with commercial interests. CogniMed staff and planners have no financial relationships with commercial interests.

Caitlin Mardis, PharmD, University of South Carolina School of Pharmacy has no financial relationships with commercial interests.

DISCLAIMERThis content and views presented in this educational activity are those of the authors and do notnecessarily reflect those of Evolve Medical Education LLC, the University of South Carolina Collegeof Pharmacy, CogniMed Inc., or Insulet Corporation. This material is prepared based upon a review ofmultiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcareprofessionals and other individuals should review and consider other publications and materials on thesubject matter before relying solely upon the information contained within this educational activity.

Claim CME/CPE Credit

Please complete the Posttest/Evaluation at cgmEDUCATION.net/roundtable

This activity is supported by an independent educational grant provided by Insulet Corporation.

Jointly provided by and

Consortium for Integrated Diabetes Device Education

TM

cgmeducation.net/query

Go to cgmEDUCATION.net/query

• Ask Questions to the Faculty• Refer a Colleague• Get CME/CPE Credit• Download Materials/Slides

cgmeducation.net/query

- or - cgmEDUCATION.net home pageclick the QueRY banner (mobile or desktop)

Consortium for Integrated Diabetes Device Education

TM

cgmeducation.net/query

Diabetes PartnersTo become a Diabetes Partner, please contact info@cgmEDUCATION.net

Be listed on our Resources PageExposure to >20,100 Members (Diabetes Specialists)Exchange information to enhance treatment outcomes for people with Diabetes

Provide additional reach to large audiences via our Social Media platforms (Twitter, Facebook and LinkedIn)

Have access to the cgmEDUCATION.net Team for any Production or Promotion needs

Consortium for Integrated Diabetes Device Education

TM

cgmeducation.net/query

Irl B. Hirsch, MDProfessor of MedicineDiabetes Treatment and Teaching ChairUniversity of WashingtonMedicine Diabetes InstituteSeattle, Washington

AID System Assessment: Where We Are in 2021

Irl B. Hirsch, MD, is professor and Diabetes Treatment and Teaching Chair at the University of Washington Medicine Diabetes Institute in Seattle.

Dr Hirsch received his medical degree from the University of Missouri School of Medicine in 1984. He completed residency training in internal medicine at Mount Sinai Medical Center in Miami and Miami Beach, Florida. Dr Hirsch also was fellowship-trained in endocrinology and metabolism at Washington University School of Medicine in St. Louis.

Dr Hirsch has dedicated his career to patient care, clinical research and teaching. His focus in these areas is the treatment and management of diabetes. He has an interest in new technologies for the treatment of diabetes, particularly those involved in the use of insulin therapy. This interest centers on the mechanisms of how insulin co-modulates inflammation with glucose and how this results in improved outcomes for patients.

He has been involved in numerous major clinical research trials, including the DCCT, ACCORD, STAR-1, JDRF Sensor Trial, SEARCH, ORIGIN, ADAG, FLAT-SUGAR, and many more involved with insulin therapy.

Additionally, he has an interest in the use of computers in diabetes data management, and how pattern recognition can be used to improve diabetes control and how glycemic variability noted on glucose meter downloads may be an independent risk for microvascular complications.

Dr Hirsch has authored more than 200 research papers, including a review of insulin in the New England Journal of Medicine. He also has written more than 60 editorials, three commentaries for The Journal of the

American Medical Association, numerous book chapters and four books for patients and physicians. He is also a much in demand national and international speaker.

He is the past editor-in-chief of DOC News and Clinical Diabetes and former chair of the Professional Practice Committee for the American Diabetes Association and served as a member of the Endocrine Section of the American Board of Internal Medicine. Currently, he is section editor for Up-To-Date.

Dr Hirsch has been honored at every level of his career, including being recognized with the Outstanding Young Physician Award by the University of Missouri Alumni Association in 2001, and in 2003 being honored as the American Diabetes Association’s Physician- Clinician of the Year. In 2005, he received the American Association of Clinical Endocrinologists’ Distinguished Endocrinologist Award, and in 2013, he received the American Diabetes Association’s Josiah K. Lilly Sr. Distinguished Service Award. In April 2015 he was elected to a Mastership by the American College of Physicians.

CHAIRPERSON

Consortium for Integrated Diabetes Device Education

TM

cgmeducation.net/query

Jennifer Sherr, MD, PhDCase Studies

Associate Professor in PediatricsYale School of MedicineNew Haven, Connecticut

Jennifer Sherr MD, PhD’s passion for the care of those with type 1 diabetes (T1D) is quite personal, as she was diagnosed in 1987. From the time of her diagnosis, she was determined to become a pediatric endocrinologist. She completed her undergraduate and medical school training through an accelerated Joint BA/MD program at Rutgers University and the University of Medicine and Dentistry of New Jersey- Robert Wood Johnson Medical School. She then completed both her pediatric residency and pediatric endocrinology fellowship at Yale. While she always wanted to care for those with T1D, her eyes were open to the meaningful impact that clinical research has. She thus embarked on further training through the Yale Graduate School of Arts and Sciences Investigative Medicine Program, a PhD program designed to develop the next generation of physician scientists.

Dr Sherr has been devoted to clinical research over the past 13 years’ time. Her thesis examined the mechanisms responsible for the loss of the glucagon response to hypoglycemia and its relationship to residual beta-cell function. Dr Sherr has since focused her career on both clinical therapeutics and technologic advancements including new glucagon formulations, adjunctive therapies for those with T1D, and new technologies including continuous glucose monitors and automated insulin delivery systems. She served as the first Junior Pediatric Faculty Member for the Type 1 Diabetes Exchange (T1DX). As an Associate Professor in the Department of Pediatrics, her goal in both the clinical and research realm is to reduce the burden of living with T1D, for both her patients and herself.

Grazia Aleppo, MD, FACE, FACPProfessor of MedicineDirector, Diabetes Education ProgramAssociate Chief for Clinical AffairsDivision of EndocrinologyMetabolism and Molecular MedicineFeinberg School of Medicine Northwestern UniversityChicago, Illinois

Case Studies Dr Grazia Aleppo graduated magna cum laude from the University of Catania School of Medicine, Catania, Italy; subesquently completed internship, residency and endocrinology fellowship at the University of Illinois at Chicago.

She is a Professor of Medicine in the Division of Endocrinology, Metabolism and Molecular Medicine at the Feinberg School of Medicine, Northwestern Uniersity, Chicago. She is also the Associate Chief for Clinical Affairs in the same Division and the Medical Director of the Northwestern Medicine Diabetes Training and Education Program.

Dr Aleppo’s clinical interest and research interest is in Diabetes, particularly in the implementation of Diabetes Technology such as Insulin pump therapy and Continuous Glucose Monitoring (CGM) therapy in clinical practice. She has participated in the major clinical trials on the use of CGM in various populations and was the protocol chair for the Replace-BG clinical trial which lead to the approval of CGM therapy for Medicare beneficiaries in the USA.

She has been very active in scholarly activities with over 50 publications and book chapters in peer reviewed journals.

She is the present Chair of the Endocrine Society Clinical Affair Core Committee. Dr Aleppo is also a fellow of the American College of Endocrinology and the American College of Physicians and a member of many professional societies, including the American Diabetes Association, the Endocrine Society, the American Association of Clinical Endocrinologists, and the American College of Physicians.

She serves on the editorial board of BMJ Open Diabetes and Research Care.

Dr Aleppo is considered a prominent national key opinion leader in the field of Diabetes Technology, including insulin pumps, CGM systems and automated insulin delivery.

Consortium for Integrated Diabetes Device Education

TM

cgmeducation.net/query

Gregory P Forlenza, MDChildren’s HospitalAssistant ProfessorBarbara Davis Diabetes Center Anschutz Campus School of MedicineUniversity of ColoradoAurora, Colorado

Novel AID Systems on the Horizon

Dr Forlenza graduated in 2007 from the University of Florida College of Medicine, where he also completed his medical residency in 2010. He is Assistant Professor at the Barbara Davis Center for Childhood Diabetes, Anschutz Campus, University of Colorado School of Medicine, as well as a Fellow of the University of Colorado Denver (2011) and the University of Minnesota, Minneapolis (2015). Dr Forlenza specializes in Diabetes and Endocrinology, Diabetes & Metabolism, and is is affiliated with Children’s Hospital, Colorado.

Dr Forlenza’s research focus is on development, refinement and testing of diabetes technology, including insulin pumps, continuous glucose monitors and the artificial pancreas. He is interested in using technology to help patients better control their diabetes and reduce the burden of diabetes on children and their families. He is site Primary Investigator (PI) on several upcoming industry pivotal trials and co-Investigator with Dr Paul Wadwa on several Juvenile Diabetes Research Foundation (JDRF) and National Institute of Health (NIH) funded projects. Dr Forlenza is also interested in islet transplantation as a potential cure for type 1 diabetes and was the co-PI for a project investigating combining islet transplantation with artificial pancreas technology. In addition, he is conducting research on the benefits of diabetes technology to minimize complications from hyperglycemia in children with cancer and children undergoing bone marrow transplantation.

Dr Forlenza’s awards and recognitions include Outstanding Resident Teacher in Pediatrics, from the University of Florida (2010), Gold Hostetter Award for Most Outstanding Research by a Fellow from the University of Minnesota Research Conference (2015), and Young Investigator Award for Outstanding Diabetes Research Under the Age of 40, from the International Society of Pediatric and Adolescent Diabetes (2019). He has authored/co-authored over 100 published articles. Dr Forlenza is very passionate about the benefits of diabetes camps and has been volunteering at various camps for over 10 years.

Consortium for Integrated Diabetes Device Education

TM

cgmeducation.net/query

>20,100 Members and growing Multi-Award WinningMedical Education

Become a Member Today!

Consortium for Integrated Diabetes Device Education

TM

Find a ClinicianPhysicians and Patients easily find and connect with You!

Add YourPractice

Now!Go to cgmEDUCATION.net/find

Refer-a-ColleagueWould a colleague be interested in cgmEDUCATION.net?

Refer aColleague

Now!Go to cgmEDUCATION.net/refer

Membership (Free) Benefits• Email updates on latest CME programs/webcasts• Early/Pre-registration for online and live meetings and programs• Access to SpeakerReady slide lecture guide• One-time log-in for all “members-only” site activities (optional)

Go to cgmEDUCATION.net/member

Consortium for Integrated Diabetes Device Education

TM

This activity is supported by an independent educational grant provided by Insulet Corporation.

Jointly provided by